Your browser doesn't support javascript.
loading
Upregulation of CXCL1 and LY9 contributes to BRCAness in ovarian cancer and mediates response to PARPi and immune checkpoint blockade.
Chen, Tingting; Yu, Tong; Zhuang, Shuping; Geng, Yiding; Xue, Junwen; Wang, Jiayi; Ai, Liqiang; Chen, Bo; Zhao, Zhangxiang; Li, Yawei; Wang, Jinghao; Liang, Haihai; Xu, Yan; Gu, Yunyan.
Afiliação
  • Chen T; Department of Systems Biology, College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang, China.
  • Yu T; Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang, China.
  • Zhuang S; Department of Systems Biology, College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang, China.
  • Geng Y; Department of Systems Biology, College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang, China.
  • Xue J; Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang, China.
  • Wang J; Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang, China.
  • Ai L; Department of Systems Biology, College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang, China.
  • Chen B; Department of Systems Biology, College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang, China.
  • Zhao Z; The Sino-Russian Medical Research Center of Jinan University, the Institute of Chronic Disease of Jinan University, the First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China.
  • Li Y; Department of Systems Biology, College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang, China.
  • Wang J; Department of Pharmacy, the First Affiliated Hospital, Jinan University, Guangzhou, Guangdong, China.
  • Liang H; Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang, China.
  • Xu Y; The Sino-Russian Medical Research Center of Jinan University, the Institute of Chronic Disease of Jinan University, the First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China.
  • Gu Y; Department of Systems Biology, College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang, China. xuyan@ems.hrbmu.edu.cn.
Br J Cancer ; 127(5): 916-926, 2022 09.
Article em En | MEDLINE | ID: mdl-35618786
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Quimiocina CXCL1 / Família de Moléculas de Sinalização da Ativação Linfocitária Tipo de estudo: Qualitative_research Limite: Female / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Quimiocina CXCL1 / Família de Moléculas de Sinalização da Ativação Linfocitária Tipo de estudo: Qualitative_research Limite: Female / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article